Europe Immunoglobulin Therapy Market Industry Trends and Forecast to 2034: Segmented by (Route, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Europe · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$3.06 BnPlaceholder estimate
Estimate 2025$3.23 Bn20.2% of the global market
Projected 2034$5.28 Bn 63.3%Adds $2.05 Bn over 9 forecast years
CAGR 2025–20345.6%Faster than 35% of 180 Pharmaceuticals markets here
Key players5
Europe is 20.16% of the global market.
Among regions, the largest is North America at $8.46 Bn.
487 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Europe Immunoglobulin Therapy Market Analysis Executive Summary
Immunoglobulin therapy gives antibodies from donated blood to treat immune deficiencies and some nerve and blood diseases.
Key segments of the immunoglobulin Therapy market include route (Intravenous and Subcutaneous) and indication (Primary Immunodeficiency, CIDP and Immune Thrombocytopenia).
Europe Immunoglobulin Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Europe Immunoglobulin Therapy Market Dynamics
Market Growth Drivers
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the immunoglobulin Therapy market. Biosimilars are widening access.
Opportunity
New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the immunoglobulin Therapy market room to grow.
Market Restraints
High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the immunoglobulin Therapy market.
Competitive Landscape for Immunoglobulin Therapy Market in Europe
The immunoglobulin Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Immunoglobulin Therapy Market in Europe
Immunoglobulin Therapy in Europe: rules, payment and research
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8] ClinicalTrials.gov lists 487 studies on Immunoglobulin Therapy that are recruiting, active or about to start in Europe.[9]
[9]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for immunoglobulin Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Route
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 CSL Behring
7.2 Takeda
7.3 Grifols
7.4 Octapharma
7.5 Kedrion
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The immunoglobulin Therapy market can be segmented based on various criteria, including route, indication and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Immunoglobulin Therapy right now, from free public sources.
Clinical trials
487 active trials in UK, Germany, France, Italy, Spain and Russia
Recruiting, about to start, or running now. Counted across the 6 countries we report on in Europe.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Immunoglobulin Therapy market in Europe?
Placeholder estimate: about $3.23 Bn in 2025, rising to about $5.28 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Immunoglobulin Therapy market in Europe growing?
Placeholder estimate: about 5.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Immunoglobulin Therapy market report cover?
The report splits the market by route (Intravenous, Subcutaneous), indication (Primary Immunodeficiency, CIDP, Immune Thrombocytopenia, Others) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Immunoglobulin Therapy market?
Key players include CSL Behring, Takeda Pharmaceutical Company Ltd, Grifols, Octapharma and Kedrion Biopharma.
What is driving the Immunoglobulin Therapy market?
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the immunoglobulin Therapy market. Biosimilars are widening access.
Who regulates Immunoglobulin Therapy in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Immunoglobulin Therapy are running in Europe?
487 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Immunoglobulin Therapy?
PubMed lists 769 papers on Immunoglobulin Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
China
Canada
Japan
Germany
UK
Italy
France
Brazil
Ecuador
Spain
India
Mexico
Saudi Arabia
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
AstraZeneca
Novartis AG
GSK PLC
Regeneron Pharmaceuticals
Johnson & Johnson
Otsuka Holdings Co Ltd